Some Analytical Considerations on the Measurement of Prostate-Specific Antigen

Clinical Chemistry and Laboratory Medicine

Volumn 34, Issue 10, 1996, Pages 817-822

  Blijenberg, Bert G ^a   Eman, Ineke ^a   Kranse, Ries ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ANALYTIC METHOD; ANTIGEN DETECTION; ARTICLE; ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC;

EID: 0029826247     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1996.34.10.817     Document Type: Article

References (16)

1. Schröder FH, Damhuis RAM, Kirkels WJ, De Koning HJ, Kranse R, Nijs HGT, Blijenberg BG. European randomized study of screening for prostate cancer -the Rotterdam pilot studies. Int J Cancer 1996; 65: 145-151.
2. Passing H, Bablok W. A new biomedical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983; 21: 709-720.
3. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
4. Hollis S. Analysis of method comparison studies. Ann Clin Biochem 1996; 33: 1-4.
5. Zhou AM, Tewari PC, Bluestein BI, Coldwell GW. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993; 39: 2483-2491.
6. Brawer MK, Daum P, Petteway, Wener MH. Assay variability in serum prostate-specific antigen determination. The Prostate 1995; 26: 1-6.
7. Wright GL, Fritsche HA. An evaluation of four commercially available immunoassays for measuring prostate-specific antigen. Presented at XXII Meeting of International Society for Oncodevelopmental Biology and Medicine; 1994 Sept 18-22; Groningen (The Netherlands). Tumor Biol 1995; 16: 317.
8. Zucchelli GC, Pilo A, Chiesa MR. Growing use of nonisotopic CA 19-9 immunoassays increases betweenlaboratory variability. Clin Chem 1993; 39: 909-911.
9. Hall M, Johnson JT, Carr J. Assays for serodiagnosis of prostate cancer. Lab Med 1992; 23: 607-612.
10. Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology 1995; 45: 173-184.
11. Murphy GP. The second Stanford conference on international standardization of prostate-specific antigen assays. Cancer 1995; 75: 122-128.
12. Wener MH, Daum PR, Brawer MK. Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995; 41: 1730-737.
13. Magic SE, Pennoyer JD. Betweenlot/betweeninstrument variations of the Abbott IMx method for prostate-specific antigen. Clin Chem 1992; 38: 2343.
14. Fritsche HA, Babaian RJ. Analytical performance goals for measuring prostate-specific antigen. Clin Chem 1993; 39: 1525-529.
15. Van Dalen A. Quality control and standardization of tumour marker tests. Tumor Biol 1993; 14: 131-135.
16. Dnistrian AN, Schwartz MK, Smith CA, Nisselbaum JS, Fair WR. Abbott IMx® evaluated for assay of prostate-specific antigen in serum. Clin Chem 1992; 38: 2140-142.